PBI-01207 is the primary active component of Anvirzel®. The extract has been well characterized (LC/MS/MS analyses of an oleander extract for cancer treatment) and consists of specific plant polysaccharides, triterpenes and other plant-derived compounds as well as the key active ingredient, oleandrin.
ANVIRZEL® has been tested in vitro, in vivo in animals, and in an FDA approved Phase I clinical study at the Cleveland Clinic. It can be obtained from Salud Integral in Tegucigalpa, Honduras. Salud Integral is an affiliate of Phoenix Biotechnology. ANVIRZEL® has been approved by the FDA for use in the U.S. for administration to humans under the Compassionate Use Investigational New Drug (CUIND) program. Please contact us for more information on obtaining access the product.
In the Phase I clinical study, ANVIRZEL® was found to be safe when administered as an intramuscular injection up to 2.4 ml per dose. Today, most patients administer the product sublingually as drops under the tongue.
ANVIRZEL® and more specifically oleandrin contained within it has a strong anticancer effect on malignant human cells, but it is not cytotoxic to normal non-malignant cells when used in appropriate doses.
ANVIRZEL® and oleandrin, its key active ingredient, exhibit anticancer properties (pharmacology) that are distinctly different from current standard of care drugs. As such, the use of ANVIRZEL® and similar extracts from Nerium oleander might be useful when combined with standard of care therapies.
For example, even though both ANVIRZEL® and PBI-05204 have been administered safely in FDA approved clinical trials and both products exhibit different overall compositional profiles, both products include different concentrations of oleandrin as the active ingredient that is primarily responsible for their biological activity. Accordingly, PBI has obtained comparative data on the therapeutic, toxicological, and pharmacological properties of ANVIRZEL® versus PBI-05204. That data has led to the finding of an overlap in biological activities between the products when normalized to oleandrin content.
The references below are just a few of those that can be obtained from PubMed that specifically mention the use of Anvirzel®. There is a much wider reference list available for all anticancer publications that mention oleandrin.
- Anvirzel® regulates cell death through inhibiting GSK-3 activity in human U87 glioma cells
- Anvirzel® in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
- Anvirzel®, an extract of Nerium oleander, induces cell death in human but not murine cancer cells
- Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel® and its cardiac glycoside component, oleandrin
- Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions
- Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity
- Cardiac glycosides in cancer research and cancer therapy
- Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process
- LC/MS/MS analyses of an oleander extract for cancer treatment
- Cardiotonic steroids attenuate ERK phosphorylation and generate cell cycle arrest to block human hepatoma cell growth
- Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander
- Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase
- Antitumor effects of oleandrin in different types of cancers: Systematic review – PDF Download
- A Role for Cardiac Glycosides in GBM Therapy
- Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2